Post-doctoral position in Bioinformatics at CRCT-toulouse (France) – immune targeting of myeloma

A postdoctoral position, with salary funded for two years is available in the team 13 “Oncogenomic and immunology of myeloma” of the Cancer research Centre of Toulouse (team 13, CRCT) directed by Dr. Martinet and Pr Avet-Loiseau. The candidate will help defining the immune landscape associated with myeloma pathogenesis through bioinformatics analysis of large data sets generated through RNAseq, single cell RNAseq, ATAC seq and flow cytometry.

Profile
We seek a highly motivated scientist that hold a Ph.D with a strong background in RNA seq, single cell RNA seq, ATAC seq analysis and knowledge in immunology. Good track record, communication and organizational skills are expected.

Offer
The position is for 2 years, available immediately. The application should contain a motivation letter, CV and contact details of 2 referees.

The Host Institute
The newly created Cancer Research Centre of Toulouse (CRCT) gathers 250 scientists from 3 public research institutions (Inserm UMR1037, Université Paul Sabatier-Toulouse III and CNRS ERL5294) that have joined their efforts to launch innovative researches against cancer. The CRCT is equipped with the most recent technological tools and platforms including fully automated animal facility, flow cytometry platform, imaging platform and Next generation sequencing platform, 10X genomics platform (see www.CRCT-inserm.fr).

City
Toulouse is located in Southwestern France close to the Pyrenees Mountains and Spain with flight and train connections to French and European cities. With more than 100,000 students and praised quality of life, it is ranked as one of the best place to live and study in France.

Project :
Although myeloma development and outcome rely on genomic alterations, recent evidences highlight the influence of the immune microenvironment in the pathogenesis of this disease. In addition, given the promising clinical responses obtained by mAbs targeting immune pathways, interest in investigating immune functions in cancer is growing exponentially. Our team has already performed some innovative research in this area (JCI 2015, Cancer cell 2018, Blood 2018) and we now aim to use complementary set of experimental approaches involving both human samples and relevant mouse models to: 1. Identify immune parameters predicting myeloma relapse and outcome 2. Identify mediators driving myeloma associated immune defects. 3. Develop and test new immunotherapeutic strategies against MM. Our research team
is highly connected with the routine Unit for Genomics in Myeloma (UGM) of the IUCT-oncopole that centralizes up to 2,500 samples per year from the different French medical centers through the IFM (Intergroupe Francophone du Myélome) network. All these annotated resources are stored for research purpose in our laboratory, with the opportunity to analyze immune parameters on large cohorts of homogeneously treated patients.

Relevant publications:


7. **Contact**: ludovic.martinet @inserm.fr